Home/Filings/4/0000908662-13-000291
4//SEC Filing

ENANTA PHARMACEUTICALS INC 4

Accession 0000908662-13-000291

$ENTACIK 0001177648operating

Filed

Nov 26, 7:00 PM ET

Accepted

Nov 27, 9:58 PM ET

Size

7.4 KB

Accession

0000908662-13-000291

Insider Transaction Report

Form 4
Period: 2013-11-26
Transactions
  • Sale

    Common Stock

    2013-11-26$25.61/sh34,446$882,124570,021 total(indirect: By Partnership)
  • Sale

    Common Stock

    2013-11-27$26.08/sh15,554$405,608554,467 total(indirect: By Partnership)
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.40 to $25.89, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.80 to $26.54, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2.
  • [F3]These shares are held by BioVentures Investors Limited Partnership II, and are shares for which Mr. Goldberg may be deemed to share voting and investment control. Mr. Goldberg disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Issuer

ENANTA PHARMACEUTICALS INC

CIK 0001177648

Entity typeoperating

Related Parties

1
  • filerCIK 0001177648

Filing Metadata

Form type
4
Filed
Nov 26, 7:00 PM ET
Accepted
Nov 27, 9:58 PM ET
Size
7.4 KB